We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 05, 2021

Exemestane, Ribociclib, and Everolimus in Women With HR+/HER2− Advanced Breast Cancer After Progression on CDK4/6 Inhibitors

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women With HR+/HER2- Advanced Breast Cancer After Progression on CDK4/6 Inhibitors (TRINITI-1)
Clin. Cancer Res 2021 Jun 18;[EPub Ahead of Print], A Bardia, SA Hurvitz, A DeMichele, AS Clark, A Zelnak, DA Yardley, M Karuturi, T Sanft, S Blau, L Hart, C Ma, HS Rugo, D Purkayastha, S Moulder

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading